Regeneron看到Q2收入增长了4%,达到3.68B,尽管监管出现延误,但主要药品销售量却有所增加。 Regeneron saw Q2 revenue rise 4% to $3.68B, with key drug sales up despite regulatory delays.

Regenenron制药公司报告说,2025年,收入增加了4%,达到36.8亿美元,调整后的每股收入为12.89美元,超过了分析师的预期。 Regeneron Pharmaceuticals reported a 4% revenue increase to $3.68 billion in Q2 2025, with adjusted earnings per share at $12.89, exceeding analyst expectations. EYLEA HDU的销售额上升29%,达到3.93亿美元。 EYLEA HD U.S. sales rose 29% to $393 million. 该公司获得了美国食品和药物管理局对多发性骨髓瘤的Lynozyfic和皮肤疾病的Dupixent的批准,并正在进行管道开发和投资制造. The company received FDA approvals for Lynozyfic for multiple myeloma and Dupixent for skin conditions, with ongoing pipeline development and investments in manufacturing. EYLEA HD监管批准工作面临延误。 EYLEA HD regulatory approvals face delays.